Release Date: December 03, 2020
Expiration Date: December 03, 2021

Target Audience:

This educational program is targeted to healthcare providers who specialize in the management of persons who use drugs (PWUD).

Educational Objectives:

On completion of this activity, the participants should be better able to:

  • Discuss data on the incidence, prevalence, and transmission of HCV in incarcerated individuals
  • Describe the detrimental effects of chronic HCV to emphasize the need for diagnosis and treatment in incarcerated individuals
  • Discuss updates in screening mandates and treatment guidelines for HCV including the importance of harm reduction and prevention of reinfection
  • Analyze the safety, efficacy, and availability of HCV treatments

Accreditation Statement and Credit Designation:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF). The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an educational grant from AbbVie.

Accredited by

Provided by


Engagement, Education, and Eradication

1.0 AMA PRA Category 1 Credit™


Introduction and Late-Breaking News
Marcelo Kugelmas, MD, FACP, FAASLD

HCV Transmission, Screening, Diagnosis and Linkage to Care
Andrew H. Talal, MD, MPH

HCV Management and Treatment Update
Marcelo Kugelmas, MD, FACP, FAASLD

Q&A, Closing Remarks
Andrew H. Talal, MD, MPH

Marcelo Kugelmas, MD, FACP, FAASLD (Chair)

Director of Hepatology and Research
South Denver Gastroenterology
Englewood, Colorado

Marcelo Kugelmas, MD received his medical degree with honors from the University of Buenos Aires. After his internship and internal medicine residency at the University of Southern California-Los Angeles County Hospital in Los Angeles, he went to Cleveland, Ohio where he completed his gastroenterology fellowship at the Cleveland Clinic Foundation and served as chief fellow in 1995. He then moved to Lexington, Kentucky where he pursued further training in hepatology, liver transplantation, and advanced endoscopy and remained there until 2000 as an assistant professor. He then moved to Colorado, where he joined the University of Colorado Liver Section. Over the last 20 years, Dr. Kugelmas' main focus has been on the care of patients with liver diseases. He became an associate professor of medicine in 2004, before joining South Denver Gastroenterology. Dr. Kugelmas is a national lecturer on topics of chronic liver disease, has presented regularly at multiple gastroenterology, liver, and transplantation annual meetings, and has published over 25 papers in peer-viewed journals.


Research Support: Allergan, Celgene, Enanta, Genfit, Genentech, Gilead, High Tida, Madrigal, North Sea, Novartis, and Viking.
Consultant: AbbVie, Gilead, Intercept, Madrigal.
Speakers Bureau: AbbVie, Gilead, Intercept.

Andrew H. Talal, MD, MPH (Co-Chair)

Professor, Department of Medicine
Director, Center for Research and Clinical Care in Liver Disease
Jacobs School of Medicine and Biomedical Sciences
University at Buffalo
Buffalo, New York

Dr. Talal is a physician-scientist with more than 20 years' experience with the hepatitis C virus (HCV), especially in disenfranchised populations, such as substance users. He is currently professor of medicine at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, where he has developed a translational liver research center and biorepository with funding from the Kaleida Health Foundation. Further, he is the principal investigator on a five-year award from the Patient-Centered Outcomes Research Institute to study telemedicine-based HCV treatment among patients on opiate agonist therapy. The study consists of 12 telemedicine sites across New York State conducting integrated treatment of HCV and opioid use disorder. Dr. Talal also conducts numerous industry-sponsored clinical drug trials that operate within the Liver Center. As a researcher, he has published over 115 papers on topics such as HCV, telemedicine, drug metabolism, and the social determinants of health. His research also led to the development of liver fine needle aspiration as a diagnostic technique for liver sampling. Dr. Talal was recently appointed by New York State Governor Cuomo to a task force to advise the state on its HCV Elimination Plan based on Dr. Talal's expertise on HCV and his use of emerging technologies to reach and to treat patients who otherwise would not have access to these services.


Grant/Research Support: Abbott, AbbVie, BMS, Conatus Pharmaceuticals, Genfit, Gilead Sciences, Inc., Intercept Pharmaceuticals, Merck, UR Center for AIDS Research, and Patient-Centered Outcomes Research Institute (PCORI).
Committee/Advisor: Abbott Diagnostics, AbbVie, Eli Lilly, Gilead, Merck, and Chronic Liver Disease Foundation.
Speakers Bureau: Chronic Liver Disease Foundation.